Preview: Fulcrum Therapeutics's Earnings
Portfolio Pulse from Benzinga Insights
Fulcrum Therapeutics (NASDAQ:FULC) is set to release its latest quarterly earnings report on Tuesday, 2023-11-07. Analysts estimate an earnings per share (EPS) of $-0.44. The company's past performance shows a pattern of beating EPS estimates, which has often led to an increase in share price. However, the stock has been down 43.72% over the last 52-week period.
November 06, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Fulcrum Therapeutics is expected to report an EPS of $-0.44 in its upcoming earnings report. The company has a history of beating EPS estimates, which has often led to a rise in share price. However, the stock has been down 43.72% over the last 52-week period.
The company's earnings report is a key event that could influence its stock price. While Fulcrum Therapeutics has a history of beating EPS estimates, which has often led to a rise in share price, the overall trend for the stock has been negative over the past year. This suggests that despite the potential for a positive earnings surprise, broader market factors and company-specific issues may be weighing on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100